结核与肺部疾病杂志2025，Vol.6Issue(4)：361-364,4.DOI:10.19983/j.issn.2096-8493.20250030
《世界卫生组织endTB方案治疗耐多药结核病指南》解读
Interpretation of the World Health Organization key updates for endTB regimens to treat multidrug-resistant tuberculosis
摘要
Abstract
Multidrug-resistant tuberculosis(MDR-TB)remains a major risk for human health.Recently,World Health Organization(WHO)has recommended new regimens for MDR-TB based on the endTB study.These regimens include drugs such as bedaquiline(Bdq),delamanid(Del),linezolid(Lzd),levofloxacin(Lfx)or moxifloxacin(Mfx),clofazimine(Cfz),and pyrazinamide(Z).Effective combinations include Bdq-Lzd-Mfx-Z,Bdq-Cfz-Lzd-Lfx-Z and Bqd-Del-Lzd-Lfx-Z.The new regimens expand the applicability of short-course regimens to MDR-TB patients with extensive lesions and are also suitable for special populations such as children,pregnant individuals,and people living with HIV.It is definitely an important event in the treatment of multidrug-resistant tuberculosis.The author briefly introduces research history,eligibility,and precautions of endTB study.关键词
结核/抗药性/治疗应用/总结性报告(主题)Key words
Tuberculosis/Drug resistance/Therapeutic uses/Consensus development conferences as topic分类
医药卫生引用本文复制引用
段鸿飞..《世界卫生组织endTB方案治疗耐多药结核病指南》解读[J].结核与肺部疾病杂志,2025,6(4):361-364,4.基金项目
北京市高层次公共卫生人才建设项目(学科带头人-03-08)Beijing High-Level Public Health Talent Development Project(Disciplinary Leader-03-08) （学科带头人-03-08）
